News

Fund+ in the news
September 22, 2021

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19   – Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues –   – Combination of IMU-838 and N4-Hydroxycytidine Reduced SARS-CoV-2 Virus Levels, Including the Delta Variant, […]

Read Post
September 16, 2021

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa   Coave to receive an upfront payment and an equity investment of €10 million and is eligible to receive further development, regulatory and commercial milestone payments of up to €65 […]

Read Post
September 1, 2021

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of […]

Read Post
August 25, 2021

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease • Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics […]

Read Post
August 18, 2021

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody   ·        Major milestone in development of “pan-coronavirus” nanobodies ·        Now evaluating clinical safety and pharmacokinetics of XVR011, a potent COVID-19 neutralizing antibody – also against Delta variant   Belgium, 18 August 2021: ExeVir, which is developing single domain antibody […]

Read Post
July 22, 2021

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform ·       Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases ·       Funding led by Seroba […]

Read Post
July 20, 2021

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of $45.0 Million Public Offering   NEW YORK, July 19, 2021 /PRNewswire/ — Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of […]

Read Post
July 15, 2021

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments Accelerated clinical development of ExeVir’s novel llama-derived antibody therapies for potential treatment and prevention of Covid-19 Manufacturing of ExeVir’s candidate product at Mithra CDMO’s new Injectable Facility Joint unique expertise of two Belgian biotechs to provide global access to innovative therapies for a broad range […]

Read Post
July 15, 2021

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement Novel lipid nanoparticles for mRNA delivery will enhance thermostability, biodegradability and safety and pave the way for new off-the-shelf therapies Niel and Ghent (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces […]

Read Post
July 13, 2021

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern Data illustrates potent neutralization activity against the Gamma and Delta Variants of SARS-CoV-2 Receives EUR3 million grant to accelerate clinical development Exevir one step closer in development of ‘pan-coronavirus’ nanobodies Belgium, July 13, 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against […]

Read Post
July 1, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis   – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory […]

Read Post
June 29, 2021

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System   ·        The objective is to make RNA therapeutics accessible to global patient populations.   ·        Makes large scale decentralized RNA production economically viable.   29 June 2021 | Niel and Brussels (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a […]

Read Post
June 23, 2021

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix® Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation eTheRNA immunotherapies NV (‘eTheRNA’, Niel, Belgium), a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, announces the expansion of its strategic collaboration with Vrije […]

Read Post
June 15, 2021

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion – Primary endpoint met, study validates autologous cell therapy 3M³ platform for bone regeneration and demonstrates manufacturing capabilities – Next generation autologous product NVD-003 to be advanced in clinical development Mont-Saint-Guibert, June 15, 2021 – Novadip Biosciences (“Novadip”), a clinical stage […]

Read Post
June 11, 2021

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics Establishes Medical Advisory Board   Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The […]

Read Post
June 3, 2021

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases Mataró, Barcelona, Spain, June 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment […]

Read Post
May 17, 2021

Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board

Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board • Brings decades of leadership experience in the Global MedTech sector • As CEO of ConvaTec Group Plc, led the $4.5 billion IPO on the London Stock Exchange • Transformed Abbott’s Diabetes Care EMEA division BELGIUM – Ghent, May 12, 2021 – Indigo Diabetes N.V. […]

Read Post
April 12, 2021

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting Additional clinical data will show benefits of leriglitazone in adrenomyeloneuropathy (AMN) Mataró, Barcelona, Spain, April 12, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan […]

Read Post
April 1, 2021

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838   NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime […]

Read Post
March 29, 2021

Michel Detheux (iTeos): ‘Biotech is als Formule 1: hoe meer geld, hoe sneller je kan gaan’

Michel Detheux (iTeos): ‘Biotech is als Formule 1: hoe meer geld, hoe sneller je kan gaan’ Michel Detheux: ‘We hebben voor de agressieve aanpak gekozen en 210 miljoen dollar opgehaald op Nasdaq. Dat was moeilijk geweest in België.’ ©M. Scott Brauer   Het Belgische biotechbedrijf Iteos Therapeutics stapte acht maanden geleden door de grote poort […]

Read Post
March 22, 2021

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million   Accelerate development of novel mRNA vaccine for hard-to-treat cancers Clinical trial to commence end of 2021   Niel, Belgium, 22 March 2021: eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of […]

Read Post
March 18, 2021

Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor

Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor Ground-breaking subcutaneous sensor aims to continuously monitor multiple metabolites including ketones in people living with diabetes BELGIUM – Ghent, March 18, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, announces that its continuous multi-metabolite […]

Read Post
March 16, 2021

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing   Extends Series A with additional EUR19 million led by Fund+ Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other […]

Read Post
March 9, 2021

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses • XVR011 antibody expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in future • Unique Llama-derived VHH72-Fc antibody (XVR011) for […]

Read Post
March 5, 2021

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases  Initial focus on development of HIV vaccine   London, United Kingdom and Niel, Belgium, March 4, 2021 – ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA […]

Read Post